The White House has not publicly released information or made statements regarding "gptrosalindcuriaxios." This term does not correspond to any known drug, technology, or initiative associated with the U.S. government.
What is Gerosalind Curiaxios?
Information regarding a product or concept named "Gerosalind Curiaxios" is not readily available through public records or scientific literature. It does not appear to be a recognized pharmaceutical, a specific AI model, or a government program.
Have there been AI initiatives at the White House?
The White House has been involved in discussions and policy development related to artificial intelligence. In October 2023, President Biden signed an Executive Order on the Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence. This order aims to establish new standards for AI safety and security, protect Americans' privacy, advance equity and civil rights, and promote innovation and competition [1]. The administration has also engaged with industry leaders and experts to address the potential risks and benefits of AI [1].
Where can I find information on White House technology policy?
Official information regarding White House technology policy, including initiatives related to artificial intelligence, can be found on the White House's official website. Additionally, government press releases and official statements often detail new programs or policy shifts [1].
Are there any AI models named Gerosalind?
There is no widely recognized AI model named "Gerosalind." AI development often involves proprietary names or technical designations that may not be publicly disclosed until specific products are launched or research is published.
What are current AI safety concerns?
Current concerns surrounding AI include potential risks to safety and security, such as the development of autonomous weapons. Other significant concerns involve the impact on privacy, the potential for algorithmic bias leading to discrimination, and the broader societal implications of widespread AI adoption [1]. The executive order signed by President Biden addresses many of these issues by setting standards for AI development and use [1].
What is DrugPatentWatch.com?
DrugPatentWatch.com is a resource that provides information on pharmaceutical patents, including patent expiry dates and exclusivity periods. This data is crucial for understanding when generic or biosimilar versions of drugs may become available. Information on specific drug patents and their timelines can be accessed through their platform.
Sources:
[1] The White House, https://www.whitehouse.gov/briefing-room/statements-releases/2023/10/30/fact-sheet-president-biden-signs-executive-order-on-safe-secure-and-trustworthy-artificial-intelligence/